The Effects of Ethanol on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Retigabine

Trial Profile

The Effects of Ethanol on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Retigabine

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Retigabine (Primary)
  • Indications Amyotrophic lateral sclerosis; Lennox-Gastaut syndrome; Partial epilepsies
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
  • Most Recent Events

    • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
    • 16 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 14 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top